Keywords: levamisole, overpriced, johnson, company, markets, anticancer, drug

J&J'S LEVAMISOLE "OVERPRICED"

Article | 01 June 1992

Print This

Johnson & Johnson, the company that markets the anticancer drug Ergamisol (levamisole) in the USA, has been criticized for overcharging for ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in